Literature DB >> 1887669

Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of beta-propiolactone.

E I Budowsky1, E A Friedman, N V Zheleznova, F S Noskov.   

Abstract

The kinetics of inactivation of the infectivity of the influenza virus by beta-propiolactone have been studied. Rate constants have been determined for inactivation of the A/Leningrad/385 (H3N2) and B/Leningrad/489/80 influenza virus under the action of beta-propiolactone on a virus-containing allantoic fluid and on a purified viral suspension. The data obtained allow calculation of the time required for inactivation of the influenza virus infectivity to a given extent in virus-containing solutions at any initial concentration of beta-propiolactone.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1887669     DOI: 10.1016/0264-410x(91)90125-p

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Reactions of beta-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses.

Authors:  Joost P Uittenbogaard; Bert Zomer; Peter Hoogerhout; Bernard Metz
Journal:  J Biol Chem       Date:  2011-08-25       Impact factor: 5.157

2.  Evaluation of Mycoplasma inactivation during production of biologics: egg-based viral vaccines as a model.

Authors:  Selwyn A Wilson David; Dmitriy V Volokhov; Zhiping Ye; Vladimir Chizhikov
Journal:  Appl Environ Microbiol       Date:  2010-03-12       Impact factor: 4.792

3.  Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs.

Authors:  James Stevens; Li-Mei Chen; Paul J Carney; Rebecca Garten; Angie Foust; Jianhua Le; Barbara A Pokorny; Ramanunninair Manojkumar; Jeanmarie Silverman; Rene Devis; Karen Rhea; Xiyan Xu; Doris J Bucher; James C Paulson; James Paulson; Nancy J Cox; Alexander Klimov; Ruben O Donis
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

4.  Vaccine-mediated protection of pigs against infection with pandemic H1N1 2009 swine influenza A virus requires a close antigenic match between the vaccine antigen and challenge virus.

Authors:  Helen E Everett; Mario Aramouni; Vivien Coward; Andrew Ramsay; Michael Kelly; Sophie Morgan; Elma Tchilian; Laetitia Canini; Mark E J Woolhouse; Sarah Gilbert; Bryan Charleston; Ian H Brown; Sharon M Brookes
Journal:  Vaccine       Date:  2019-03-23       Impact factor: 3.641

5.  Effect of formaldehyde inactivation on poliovirus.

Authors:  Thomas Wilton; Glynis Dunn; David Eastwood; Philip D Minor; Javier Martin
Journal:  J Virol       Date:  2014-08-06       Impact factor: 5.103

6.  Evaluation of Immunoreactivity and Protection Efficacy of Seneca Valley Virus Inactivated Vaccine in Finishing Pigs Based on Screening of Inactivated Agents and Adjuvants.

Authors:  Wenqiang Liu; Xiangmin Li; Huawei Zhang; Genxi Hao; Xianfei Shang; Huilan Wang; Huanchun Chen; Ping Qian
Journal:  Vaccines (Basel)       Date:  2022-04-18

7.  Solid bioneedle-delivered influenza vaccines are highly thermostable and induce both humoral and cellular immune responses.

Authors:  Peter C Soema; Geert-Jan Willems; Klaas van Twillert; Gijsbert van de Wijdeven; Claire J Boog; Gideon F A Kersten; Jean-Pierre Amorij
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

8.  Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production.

Authors:  José Herrera-Rodriguez; Aurora Signorazzi; Marijke Holtrop; Jacqueline de Vries-Idema; Anke Huckriede
Journal:  Vaccine       Date:  2019-02-11       Impact factor: 3.641

9.  Differential antigen presentation regulates the changing patterns of CD8+ T cell immunodominance in primary and secondary influenza virus infections.

Authors:  Sherry R Crowe; Stephen J Turner; Shannon C Miller; Alan D Roberts; Rachel A Rappolo; Peter C Doherty; Kenneth H Ely; David L Woodland
Journal:  J Exp Med       Date:  2003-07-28       Impact factor: 14.307

10.  Propagation, Inactivation, and Safety Testing of SARS-CoV-2.

Authors:  Alexander S Jureka; Jesus A Silvas; Christopher F Basler
Journal:  Viruses       Date:  2020-06-06       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.